---
title: Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
nct_id: NCT03113409
overall_status: TERMINATED
phase: PHASE2, PHASE3
sponsor: New York State Psychiatric Institute
study_type: INTERVENTIONAL
primary_condition: Opioid-use Disorder
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03113409.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03113409"
ct_last_update_post_date: 2022-03-02
last_seen_at: "2026-05-12T07:24:17.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

**NCT ID:** [NCT03113409](https://clinicaltrials.gov/study/NCT03113409)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** no funding available to continue
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** New York State Psychiatric Institute
- **Conditions:** Opioid-use Disorder
- **Start Date:** 2017-06-01
- **Completion Date:** 2020-12-01
- **CT.gov Last Update:** 2022-03-02

## Brief Summary

The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX. There will be three different methods of XR-NTX induction using increasing doses of oral naltrexone and buprenophine.

## Detailed Description

Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.

Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.

Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.

All participants will receive weekly therapy with a study psychiatrist. All participants will receive open-label medication.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Age 18-60.
2. Meets DSM-5 criteria for current opioid use disorder (moderate-severe) of at least six months duration, supported by urine toxicology OR COWS score \> or =6 OR Naloxone Challenge.
3. Voluntarily seeking treatment for opioid dependence.
4. In otherwise good health based on complete medical history and physical examination within normal ranges (AST or ALT \< 3 times normal). )
5. Able to give written informed consent.

Exclusion Criteria:

1. Methadone maintenance treatment or regular use of illicit methadone (\> 30 mg per week).
2. Maintenance on, or regular use of buprenorphine or other long-acting narcotic agonists.
3. Pregnancy, lactation, or failure in a sexually active woman to use adequate contraceptive methods.
4. Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with AST or ALT \> 3 times normal, AIDS (CD4 count under 200 currently or medically ill with an opportunistic infection), unstable diabetes.
5. Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder, severe Major Depressive Disorder, or suicide risk or 1 or more suicide attempts within the past year.
6. Physiologically dependent on alcohol or sedative- hypnotics with impending withdrawal. Other substance use diagnoses are not exclusionary.
7. History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.
8. Chronic organic mental disorder (e.g. AIDS (CD4 count under 200 currently or medically ill with an opportunistic infection) dementia).
9. History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.
10. Painful medical condition that requires ongoing opioid analgesia or anticipated surgery necessitating opioid medications.
```

## Arms

- **Procedure 1** (EXPERIMENTAL) — Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
- **Procedure 2** (EXPERIMENTAL) — Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
- **Procedure 3** (EXPERIMENTAL) — Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.

## Interventions

- **Buprenorphine** (DRUG) — Buprenorphine will be administered daily
- **Naltrexone** (DRUG) — On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
- **Vivitrol** (DRUG) — Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.

## Primary Outcomes

- **Percentage of Patients Who Receive the Second Injection of XR-NTX.** _(time frame: 4 weeks after 1st injection)_ — Percentage of patient who initiated Procedure 1 and completed the study receiving the 2nd injection of XR-NTX

## Locations (1)

- New York State Psychiatric Institute, New York, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.new york state psychiatric institute|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03113409.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03113409*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*